Education
About Us
Working with TipRanks
Follow Us
Baudax Bio Inc (BXRXQ)
:BXRXQ
BXRXQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume10.20K
Average Volume (3M)N/A
Market Cap
$44.00
Enterprise ValueN/A
Total Cash (Recent Filing)$363.00K
Total Debt (Recent Filing)$8.10M
Price to Earnings (P/E)―
Beta-150.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.16
Shares Outstanding43,593,082
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BXRXQ FAQ
What was Baudax Bio Inc’s price range in the past 12 months?
Baudax Bio Inc lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Baudax Bio Inc’s market cap?
Baudax Bio Inc’s market cap is $44.00.
When is Baudax Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baudax Bio Inc’s earnings last quarter?
Currently, no data Available
Is Baudax Bio Inc overvalued?
According to Wall Street analysts Baudax Bio Inc’s price is currently Overvalued.
Does Baudax Bio Inc pay dividends?
Baudax Bio Inc does not currently pay dividends.
What is Baudax Bio Inc’s EPS estimate?
Baudax Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baudax Bio Inc have?
Baudax Bio Inc has 43,593,082 shares outstanding.
What happened to Baudax Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baudax Bio Inc?
Currently, no hedge funds are holding shares in BXRXQ
Company Description
Baudax Bio Inc
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Biodexa Pharmaceuticals
―
Nuwellis
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---